Oral AML Treatment for Some Older Adults: What an FDA Approval Does—and Does Not—Say

The approval, in one paragraph

On May 13, 2026, the Food and Drug Administration approved a pill form of two drugs, decitabine and cedazuridine, sold as Inqovi. The pills are taken with venetoclax, another pill. The approval covers newly diagnosed acute myeloid leukemia, or AML, in adults age 75 and older. It also covers adults whose other health problems rule out intensive induction chemotherapy. That is the whole group named in the label.

Who the label leaves out

Most people with AML are not in that group. Younger adults who can take intensive chemotherapy are not covered. Neither are people whose AML has come back after earlier treatment. Neither are people already on a different first treatment.

Age alone does not decide this. A healthy 78-year-old and a frail 78-year-old may be offered different plans. Doctors weigh heart function, kidney function, past infections, and how well a person moves through a normal day.

What the study actually measured

The FDA notice names the study: ASTX727-07. It enrolled 101 adults. It had one arm. Everyone in it got the same regimen. Nobody was assigned to a comparison group.

Of those 101 adults, 42 had a complete remission. That is 41.6 percent. The median time to reach remission was two months. The median length of remission was not yet reached when the FDA reviewed the data.

A single-arm study can show that a regimen works. It cannot show that this regimen beats the older shot-based version. No head-to-head trial has answered that. Any headline that says "better" is going past what the study can prove.

Oral does not mean gentle

Pills are easier to take than infusions. They are not milder. The FDA notice lists warnings for myelosuppression, which means very low blood counts. It also lists harm to a developing fetus.

Low counts bring real risk. Infection, bleeding, and the need for transfusions are all part of AML care. Blood tests do not stop when the drug moves from a bag to a bottle. Many people still come to the clinic often.

The dose in the label is one tablet a day on days 1 through 5 of each 28-day cycle. Treatment goes on until the disease grows or the side effects become too much. That is a long-running routine, not a short course.

The home-medicine problem nobody puts in the headline

Taking cancer drugs at home shifts work onto the person and the family. Someone has to track doses, spot a fever at 2 a.m., and know when to call. Venetoclax also interacts with many common drugs, including some antifungals and heart medicines.

Older adults often take several prescriptions already. Our guide to managing many medicines at once covers the questions worth raising before a new pill is added.

What has not changed

AML subtype and gene findings still guide the plan. So do fitness, other illnesses, and what a person wants from treatment. A new approval adds an option. It does not replace the full range of treatment choices, including intensive chemotherapy, transplant, a clinical trial, or comfort-focused care.

Questions for the care team

• Do I meet the exact label criteria, or is this being used off-label?
• How often will my blood counts be checked, and where?
• Which of my current medicines interact with venetoclax?
• What would intensive treatment or a clinical trial offer me instead?
• Who do I call at night if I spike a fever?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.